Today’s Winner And Loser: GW Pharmaceuticals plc Pushes Higher As Circle Holdings PLC Slumps

GW Pharmaceuticals plc (LON: GWP) is charging higher while Circle Holdings PLC (LON: CIRC) slumps following the cancellation of a contract.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in Circle Holdings (LSE: CIRC) have slumped by more than a fifth today, after the company revealed that it was pulling out of the contract to Hinchingbrooke Health Care NHS Trust. Management has determined that the contract to manage the hospital is no longer sustainable, citing a cut in funding for the hospital as the main reason why the franchise is no longer viable.

According to Circle, government funding for Hinchingbrooke has been cut by 10% this year. Management believes that, after this funding cut, Circle would have to make a substantial investment in the franchise on top of the £5m it is already required to provide. 

Of this £5m investment, Circle has already provided £4.8m. So, under the contract Circle is require to provide an additional £160,000 to Hinchingbrooke in addition to contract termination and re-procurement costs, which are capped at £2m. 

According to City analysts, this move by Circle will have no effect on pre-tax profit for 2015 and 2016. — the company is currently forecast to report a pre-tax loss of £7m for 2015 and loss of £6.8m for 2016 — however, pre-tax profitability for 2017 and 2018 is expected to be affected by £3m and £4m respectively. 

And it remains to be seen how this move will affect Circle’s ability to win additional contracts with the NHS in future. As well as Hinchingbrooke, the group has also been awarded a £125m contract to provide musculoskeletal services for 440,000 patients in Bedfordshire for five years and is in the running to manage George Eliot hospital in Nuneaton.

Until the repercussions of this move are clear, Circle’s future is uncertain. 

Drug failure 

As Circle slumps, GW Pharmaceuticals (LSE: GWP) is charging higher today, after announcing yesterday that one of three Phase III cancer pain trials of its Sativex compound failed to meet its primary endpoint. After releasing the news yesterday, GW’s shares fell as much as 21% at one point but they quickly recovered and they ended the day unchanged. 

Even though one of GW’s trails has failed, the company still has two additional trials under way. If these trials yield positive results, GW would be able to submit a new drug application with the US Food and Drug Administration.

Furthermore, within yesterday’s update, GW said that all of its trials in its Epidiolex programme for treatment-resistant childhood epilepsies are on track. Phase III data from at least one of its trials now expected by the end of 2015.

Overall, even though one of GW’s trails failed to yield the desired results, the company still has plenty of irons in the fire. That being said, investors should keep in mind that only 7% of all new drugs successfully make it from the research and development stage, through to commercial production. So the odds are stacked against GW. 

Nevertheless, only you can decide if GW fits in your portfolio and I thoroughly recommend that you do some additional research before making a trading decision. And if you do decide to buy GW, or Circle, a basket approach will work best.  

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »